The loop diuretic market — a class of medications including furosemide, bumetanide, torsemide, and ethacrynic acid that block the Na-K-2Cl cotransporter in the kidney's loop of Henle to treat fluid overload conditions like heart failure, nephrotic syndrome, cirrhosis, and hypertension — remains anchored by a decades-old drug that clinical evidence increasingly suggests may not be...